|
Summary
July 2008, Vol. 7, No. 4, Pages 377-387
, DOI 10.1517/14740338.7.4.377
The safety of cefepime in the treatment of infectionLorenzo Drago † PhD & Elena De Vecchi MScUniversity of Milan, Laboratory of Clinical Microbiology, Department of Preclinical Science, LITA Vialba, Via GB Grassi 74, 20157 Milan, Italy +39 2 5031 9833; +39 2 5031 9651; lorenzo.drago@unimi.it † Author for correspondence Background: Cefepime is a fourth-generation cephalosporin usually reserved for treating severe nosocomial pneumonia, as well as empirical treatment of febrile neutropenia, uncomplicated and complicated urinary tract infections, uncomplicated skin and skin structure infections, and complicated intra-abdominal infections. Objective: Since reports of neurotoxic effects and of an all-cause mortality higher with cefepime than with comparators have created some concerns regarding its safety, this paper reviews data available in the PubMed database up to December 2007 on cefepime safety. Methods: Literature data from PubMed obtained by combining cefepime and safety, or cefepime and clinical trials, were examined. Results/conclusions: Caution in the use of cefepime should be adopted until new evidence on cefepime safety is available.
| The use and safety of doxycycline hyclate and other second-generation tetracyclines Barry Sloan, Noah ScheinfeldSummary
| Full Text
| PDF (248 KB)
| PDF Plus (217 KB)
|
Add to Favorites
| Related | |
| Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome Martin C MichelSummary
| Full Text
| PDF (277 KB)
| PDF Plus (258 KB)
|
Add to Favorites
| Related | |
| Imatinib mesilate for the treatment of gastrointestinal stromal tumour Philippe A Cassier, Armelle Dufresne, Samia Arifi, Hiba El Sayadi, Intidar Labidi, Isabelle Ray-Coquard, Séverine Tabone, Pierre Méeus, Dominique Ranchère, Marie-Pierre Sunyach, Anne-Valérie Decouvelaere, Laurent Alberti, Jean-Yves BlaySummary
| Full Text
| PDF (171 KB)
| PDF Plus (276 KB)
|
Add to Favorites
| Related | |
|
|
|